What is Cartesian Therapeutics?
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to advancing mRNA cell therapies for the treatment of autoimmune diseases. The company's lead candidate, Descartes-08, is an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy currently in Phase 2b clinical development for generalized myasthenia gravis. Further applications are being explored for systemic lupus erythematosus and myeloma autoimmune basket trials. Cartesian is also developing Descartes-15 for autoimmune diseases and myeloma, and Descartes-33, which is in preclinical stages for autoimmune disease treatment. The company's focus on engineered cell therapies represents a cutting-edge approach within the biopharmaceutical landscape.
How much funding has Cartesian Therapeutics raised?
Cartesian Therapeutics has raised a total of $130M across 1 funding round:
Other Financing Round
$130M
Other Financing Round (2024): $130M with participation from HBM Healthcare Investments
Key Investors in Cartesian Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market, driven by demographic trends, medical advancements, and increasing demand for innovative therapies.
What's next for Cartesian Therapeutics?
With this substantial enterprise-level funding, Cartesian Therapeutics is poised to accelerate its clinical development programs and expand its research initiatives. The strategic investment will likely fuel the progression of Descartes-08 through its later-stage trials and advance the preclinical pipeline, including Descartes-15 and Descartes-33. This capital will also support the company's ongoing efforts to scale operations and potentially explore new therapeutic targets within the autoimmune disease space, reinforcing its position as a key innovator in the biotechnology sector.
See full Cartesian Therapeutics company page
